Message :
Required fields Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45
National Task Force supports Cologuard
® as a screening option and screening expands to an additional
˜19 million Americans
MADISON, Wis.-
May 18, 2021 - The United States Preventive Services Task Force (USPSTF) today released its final colorectal cancer screening recommendationthat screening begin at age 45. Exact Sciences (NASDAQ: EXAS) Cologuard
®, referred to as sDNA-FIT, is included as a recommended screening option for all average-risk patients between the ages of 45 and 75. Colorectal cancer is the second leading cause of cancer death in the United States, in part because many cancers go undetected until later stages when treatment options are limited.
Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most cost-effective colorectal cancer (CRC) screening option in the Alaska Native population, as compared to colonoscopy and the fecal immunochemical test (FIT), for a wide range of adherence scenarios. According to the model, Cologuard produced the highest number of quality adjusted life years (QALYs) gained and the largest reduction in CRC incidence.
1
Colorectal cancer is the second leading cause of cancer death for men and women in the United States,
2 in part because many cancers go undetected until later stages when treatment is less effective.
3 Alaska Native (AN) people have among the nation s highest reported incidence rates for CRC, at 89.0 per 100,000 people compared to 45.7 per 100,000 people for the entire United States.